• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should Earnings Growth Require Action From Revvity (RVTY) Investors?

    Simply Wall St·10/27/2026 20:13:36
    Listen to the news
    • Revvity is set to report third quarter 2026 results on 3 November, with Wall Street expecting higher earnings supported by stronger revenue.
    • Analysts highlight the company’s recent record of outperforming earnings estimates as a key test of how efficiently Revvity is running its operations.
    • This report will examine how Revvity's investment narrative is affected by expectations of year over year earnings growth in the upcoming quarter.

    Scan how Wall Street's earnings enthusiasm around Revvity compares with peers by lining up its setup against our hand picked 29 high quality undervalued stocks.

    Revvity Investment Narrative Recap

    To own Revvity, you need to believe its mix of health sciences tools, diagnostics and software can turn modest revenue progress into faster earnings and cash flow growth. The immediate focus is whether reproductive health, ex China immunodiagnostics and Signals software are still doing the heavy lifting, or if momentum is starting to cool.

    The coming third quarter print is a live check on that thesis. A cleaner view of operating margins after past one off items is the key short term catalyst. The biggest risk is that earnings quality or growth in higher margin areas looks less durable than recent enthusiasm around Revvity implies.

    The most relevant data point right now is Revvity's track record of beating earnings expectations in each of the last four quarters, with an average surprise of 6.59%. That history sets a high bar around execution and cost control. It also makes any slip in profitability or cash generation more important than usual for investors watching near term drivers.

    Consensus expects third quarter EPS to be up 9.3% year over year. The print will indicate how the business is balancing slower forecast revenue expansion of about 5% annually with faster projected earnings growth of about 22% per year. If growth in software, reproductive health and immunodiagnostics is not clearly supporting that spread, the risk side of the Revvity story becomes more prominent.

    What The Current Long Range Forecast Implies For Revvity

    Revvity's long range model depends on a relatively modest top line lift doing a lot of work for earnings. Analysts are penciling in 4.4% a year revenue growth over the next three years, while expecting profit margins to almost double from 8.2% today to 16.3% in that window. The story only really holds together if that margin expansion from software, reproductive health and ex China immunodiagnostics continues to play its part.

    On the earnings line, the consensus view is clear enough. Forecasts sit at US$540.0 million of profit by around 2029, compared with US$237.4 million today. That implies earnings a little more than 2x current levels, with the gap between bullish and bearish estimates wide, from US$355.8 million to US$726.8 million. For investors, the question is less about the precision of those numbers and more about comfort with the range of possible outcomes that analysts are flagging.

    The valuation road map is equally explicit. To land near the consensus, you would have to assume that by 2029 Revvity generates about US$3.3b of revenue and delivers that US$540.0 million of earnings, while the stock trades on a P/E of 37x. That would be a meaningfully lower multiple than the 71.8x applied to today's earnings and below the current US life sciences sector at 42.3x. This setup indicates that the market already incorporates substantial profit growth into the price, leaving less room for further multiple expansion than in the past.

    Revvity's narrative projects about US$3.3b revenue and US$540.0 million earnings by 2029. This rests on 4.4% yearly revenue growth and an earnings increase of roughly US$302.6 million from US$237.4 million today.

    Uncover why Revvity's fair value signals an 8% potential downside to its current price, which leaves little room for error.

    NYSE:RVTY 1-Year Stock Price Chart
    NYSE:RVTY 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view puts Revvity’s software and AI tools at the center of the story. The most optimistic analysts were modeling about US$3.4b of revenue and US$725.8 million of earnings by 2029, well above consensus. That is a much brighter setup than the baseline. With the upcoming earnings release, those assumptions may shift, so treat this as one of several viewpoints to explore.

    Explore 2 other Revvity fair value estimates, including one that suggests up to 9% upside from the current price.

    The Verdict Is Yours

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more investment ideas beyond Revvity?

    If Revvity has sharpened your thinking and you want to stress test that framework against a wider opportunity set, the Simply Wall St Screener can help you quickly sort through companies that fit very specific risk, quality or income goals.